1. Home
  2. BLX vs AUPH Comparison

BLX vs AUPH Comparison

Compare BLX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$51.17

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$14.23

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLX
AUPH
Founded
1977
1993
Country
Panama
Canada
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
BLX
AUPH
Price
$51.17
$14.23
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$17.25
AVG Volume (30 Days)
154.2K
836.9K
Earning Date
02-12-2026
02-26-2026
Dividend Yield
5.37%
N/A
EPS Growth
8.75
N/A
EPS
6.09
0.55
Revenue
$317,451,000.00
$265,808,000.00
Revenue This Year
$18.17
$21.76
Revenue Next Year
$6.12
$16.45
P/E Ratio
$8.40
$25.87
Revenue Growth
10.87
20.62
52 Week Low
$31.14
$6.55
52 Week High
$51.49
$16.54

Technical Indicators

Market Signals
Indicator
BLX
AUPH
Relative Strength Index (RSI) 72.48 38.73
Support Level $49.33 $14.21
Resistance Level $49.78 $14.66
Average True Range (ATR) 1.12 0.45
MACD 0.13 -0.02
Stochastic Oscillator 92.87 3.88

Price Performance

Historical Comparison
BLX
AUPH

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: